This oncosuppressor miRNA controls the expression of two oncoproteins BRAF and MDM2, is strongly downregulated in BRAF-mutated melanomas and is able to impair the development of resistance to MAPK inhibitors. The gene discussed is BRAF; the disease is melanoma.